STOCK TITAN

Regen BioPharma PFD A (RGBPP) 10-K Filings

RGBPP OTC

Here are the 10-K annual reports from Regen BioPharma PFD A (RGBPP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow RGBPP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RGBPP filings page.

Rhea-AI Summary

Regen Biopharma, Inc. is an early-stage Nevada biotech focused on regenerative medicine and immuno-oncology, with no clinical trials yet started and no conclusions of efficacy for its product candidates. The company is developing several NR2F6‑targeted programs, including HemaXellerate for severe aplastic anemia, dCellVax and tCellVax cell therapies, DiffronC and DuraCar for solid tumors, plus small‑molecule NR2F6 modulators, all in pre‑clinical or IND‑stage development.

Regen controls a portfolio of issued U.S. patents around NR2F6 modulation, cancer vaccines, and gene‑silencing technologies and monetizes some of this IP through licenses, notably to Zander Therapeutics for veterinary uses and to Oncology Pharma for human pancreatic and colon cancer indications, with upfront fees, royalties of 4–5% of Net Sales, and 10% of sublicense consideration. As of December 26, 2025, the company had 108,054,704 common shares outstanding and multiple preferred series, following a 1‑for‑1500 reverse split and a 2024 Series A preferred stock dividend, and continues to fund operations through Regulation A offerings, convertible notes, and share issuances for debt settlement and consulting services.